

Patent Docket P1726R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Leonard Presta Serial No.: 09/483,588 Filed: January 14, 2000 For: POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION</p>	<p>Group Art Unit: 1644 Examiner: D. Saunders</p> <hr/> <p>Certificate of Facsimile Transmission Under 37 CFR § 1.8 In accordance with CFR § 1.6(d), this correspondence addressed to The Patent and Trademark Office, Washington, DC 20231 is being transmitted to facsimile No. (703) 872-9306</p> <p>December 3, 2002 <i>Wendy M. Lee</i> Wendy M. Lee</p>
--	---

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Responsive to the Office Action mailed 9/3/02 (Paper #14), reconsideration of the present application is respectfully requested in view of the following amendments and remarks.

IN THE CLAIMS:

Please amend independent claims 1 and 14 as follows:

1. (Amended) A variant of a parent polypeptide comprising a human IgG Fc region, which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively, or binds an Fc gamma receptor III (FcγRIII) with better affinity, than the parent polypeptide and comprises two or more amino acid substitutions in the Fc region.

14. (Amended) A polypeptide comprising a variant Fc region with increased binding to an Fc gamma receptor (FcγR), which polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 312, 315, 324, 326, 327, 329, 330, 333, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398,